Capricor Therapeutics' (CAPR) "Buy" Rating Reiterated at HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $77.00 price objective on the biotechnology company's stock.

A number of other research firms have also issued reports on CAPR. Roth Capital restated a "buy" rating and set a $31.00 price target on shares of Capricor Therapeutics in a report on Tuesday, June 17th. Oppenheimer dropped their price objective on Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research note on Monday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Finally, Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, Capricor Therapeutics has an average rating of "Moderate Buy" and an average target price of $36.67.

Capricor Therapeutics Trading Up 9.9%

Shares of NASDAQ CAPR traded up $0.76 during midday trading on Tuesday, reaching $8.44. 3,301,493 shares of the stock were exchanged, compared to its average volume of 1,863,740. The stock has a 50 day moving average price of $10.91 and a 200-day moving average price of $12.46. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40. The company has a market capitalization of $385.68 million, a P/E ratio of -5.94 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The company had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same period last year, the firm posted ($0.31) earnings per share. On average, analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Trading of Capricor Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Capricor Therapeutics by 44.4% during the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock valued at $31,420,000 after acquiring an additional 700,243 shares during the last quarter. Farallon Capital Management LLC purchased a new stake in Capricor Therapeutics in the fourth quarter worth about $31,056,000. Geode Capital Management LLC raised its holdings in Capricor Therapeutics by 37.8% in the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock worth $12,139,000 after purchasing an additional 241,279 shares in the last quarter. Woodline Partners LP increased its stake in shares of Capricor Therapeutics by 15.8% during the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company's stock valued at $6,921,000 after purchasing an additional 99,384 shares in the last quarter. Finally, Altium Capital Management LLC grew its stake in shares of Capricor Therapeutics by 150.5% in the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock worth $9,853,000 after acquiring an additional 429,000 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.